Purpose and appropriate sample types
This 27-color flow cytometry antibody panel allows broad immune-profiling of major leukocyte subsets in human whole blood (WB). It includes lineage markers to identify myeloid and lymphoid cell populations including granulocytes, monocytes, myeloid dendritic cells (mDCs), natural killer (NK) cells, NKT-like cells, B cells, conventional CD4 and CD8 T cells, γδ T cells, mucosa-associated invariant T (MAIT) cells and innate lymphoid cells (ILC). To further characterize each of these populations, markers defining stages of cell differentiation (CCR7, CD27, CD45RA, CD127, CD57), cytotoxic potential (perforin, granzyme B) and cell activation/proliferation (HLA-DR, CD38, Ki-67) were included. This panel was developed for quantifying absolute counts and phenotyping major leukocyte populations in cryopreserved, fixed WB collected from participants enrolled in large multi-site tuberculosis (TB) vaccine clinical trials (Table 1). This antibody panel can be applied to profile major leukocyte subsets in other sample types such as fresh WB or peripheral blood mononuclear cells (PBMCs) with only minor additional optimization.
Keywords: Immunophenotyping, high-dimensional flow cytometry, absolute counts, fixed whole blood, clinical trials, immune cell subsets
1. Background
We developed this antibody panel in the context of a research program that aims to identify vaccine-induced immune correlates of protection against Mycobacterium tuberculosis infection or TB disease (1). The panel was designed to enumerate and phenotype relevant leukocyte subsets that may be modulated by vaccination in fixed whole blood samples collected from participants enrolled in large TB vaccine clinical trials. We applied a procedure termed Differential Leukocyte Counting and Immunophenotyping in Cryopreserved Ex vivo whole blood (DLC-ICE) (2), based on erythrocyte lysis and cell fixation of a precise volume of blood, prior to cryopreservation. After thawing in batches, fixed cells are permeabilized and stained with the antibody panel, and reference fluorescent microbeads are added to the final cell suspension to accurately determine absolute cell counts by flow cytometry. Use of cryopreserved fixed whole blood in this assay offers multiple benefits compared to other flow cytometry-based methods, including reduction of procedural complexity and workload at the point of sample collection, cost-effectiveness, improvement and reduction of data variability, especially in extensive studies involving multiple sites in resource-limited settings. In a previous report, we demonstrated accuracy, robustness, low inter-operator variability of this method and high concordance of readouts including a wide range of absolute counts and frequencies when fresh and cryopreserved fixed WB samples from the same donors were stained with a similar 27-color panel (3). These results suggest that fixation/permeabilization and cryopreservation steps do not affect the detection and resolution of the selected antibody-marker combinations. Markers included in this panel allow broad analysis of most lymphoid populations, while myeloid subsets can also be characterized to a lesser extent, as described below (Figure 1 and Online Figure 1).
Granulocytes are identified by the expression of CD66, a member of the carcinoembryonic antigen (CEA) family and related to the immunoglobulin superfamily of glycoproteins. Also called polymorphonuclear neutrophilic leukocytes (PMNs), granulocytes include three different types of subsets namely, neutrophils, basophils and eosinophils. We selected the anti-CD66 antibody B1.1 clone, which recognises isoforms that are expressed solely by neutrophils in the blood. Phagocytic neutrophils recognize and internalize pathogenic microorganisms by phagocytosis into microbicidal acidified phagolysosomes, where the organisms are killed through release of antimicrobial enzymes stored in their cytoplasmic granules (4).
Myeloid and lymphoid cells can be distinguished using CD33 expression and side scatter. Monocytes can be divided into three populations based on their CD14 and CD16 expression, namely classical (CD14high CD16−), intermediate (CD14int CD16int) and non-classical (CD14−CD16+) monocytes. Myeloid DCs, also named conventional DCs (cDCs), are CD14 and CD16 negative and express high levels of CD11c and HLA-DR. Defined as professional antigen-presenting cells, mDCs are crucial for T cell priming. Through their ability to process ingested pathogens and present microbial peptide antigens to T cells while providing essential co-stimulatory signals, they orchestrate T cell activation and differentiation in response to microbial recognition (5). We did not include CD123, which precluded precise identification of plasmacytoid DC (pDCs, CD123+ CD11c−) with our panel.
We included two Fc receptors (FcRs), CD32 and CD16, in our panel because of the recently described role of Fc-mediated functions in protection against malaria following vaccination (6). As receptors for the Fc portion of immunoglobulins (Ig), FcRs are transmembrane glycoproteins expressed by a variety of leukocytes including granulocytes, monocytes, B and NK cells. FcR cross-linking mediates positive and negative regulation of cellular signalling including phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), production and release of cytokines and pro-inflammatory molecules. Importantly, FcRs can also induce clearance of immune complexes. In fact, following capture and internalization/degradation of antigen-antibody complex, peptide antigens are presented to cells in an MHC-restricted manner. The largest family of Fc receptors are the IgG receptors or FcγRs which themselves contain several groups: FcγRI/CD64, the high affinity IgG receptor, the FcγRII/CD32 family (FcγRIIA, FcγRIIB, FcγRIIC), and the FcγRIII/CD16 family (7).
Amongst the CD3− cells, we were able to distinguish B cells and several stages of their differentiation. Rather than CD20, we decided to stain for CD19, which is also expressed by plasmablasts, a rare B cell subset expressing CD27 and CD38 at high levels. While they can secrete antibodies at high rate, plasmablasts divide and express surface Ig and MHC class II, allowing antigen presentation to T cells. Following division, they either die or undergo differentiation into short or long-lived plasma cells, the latter migrating to bone marrow (8). Plasmablasts are typically absent or detectable at very low frequencies in healthy individuals, but frequencies usually transiently increase after vaccination. Based on CD27 and IgD expression, memory (IgD−CD27+) and naïve (IgD+CD27−) B cells can be distinguished. However, even if we observed CD27 staining patterns as expected on T cells, we note that the resolution of CD27 staining was poor on B cells. We recommend testing different CD27 clones and fluorochrome conjugates if CD27 measurement on B cells is an essential desired outcome in other studies. Expression of IgM and IgG isotypes allow class switch identification, but these markers were not included in our panel due to low priority and poor resolution of staining in fixed whole blood, respectively. Similarly, CXCR5, a chemokine receptor for CXCL13 and important soluble factor for germinal center establishment and maintenance, was tested during panel optimisation, but resulted in particularly poor resolution on T cells and therefore was excluded. ILCs were identified using CD127 after exclusion of most lineage markers.
NK cells, defined as CD3−CD56+CD16+/−, are innate cells with the ability to kill infected cells. Their cytolytic granules, containing pore-forming protein perforin and granzymes are released at the surface of the target cell and can penetrate the cell membrane to mediate programmed cell death (9). NK cells can be classified into two main types based on expression of CD56 and CD16: highly cytotoxic CD56dimCD16+ mature cells and CD56briCD16− immature cells that can produce cytokines, especially IFN-γ, that can polarize CD4 T cells towards Th1 pro-inflammatory cells. In this panel, we included the cytotoxic markers perforin and granzyme B. CD57 and CD27 were included as NK (and T) cell differentiation markers, facilitating the delineation of NK cell maturation from CD56bri to CD56dimCD57+ cells, which have decreased proliferative but retain highly cytotoxic capacity (10, 11). Of note, in another study, CD57+ NKG2C+ NK cells revealed memory-like properties specific to acute MCMV infection (12). Similarly, Venkatasubramanian et al. suggested CD27 as a potential ‘memory’ marker for BCG-induced memory-like NK cells (13).
Donor-unrestricted T cells (DURT cells) include MR1-restricted MAIT cells, CD1-restricted invariant NKT (iNKT) cells, germline-encoded mycolyl-reactive (GEM) cells, glucose monomycolate-reactive (GMM) cells, and γδ T cells. DURT cells recognize non-peptide antigens such as lipids, vitamin B metabolites or phosphoantigens presented by non-polymorphic MHC-like and non-MHC-like molecules (i.e CD1d for iNKT, MR1 for MAIT, CD1b for GMM cells) (14). While MAIT and CD1-restricted DURT cells predominantly recognize antigens via αβ T cell receptors (TCRs), γδ T cells recognize antigens via γδ TCRs. Vδ2+ γδ T cells are the most dominant subset of γδ T cells in adult human blood and can be profiled with this panel (15). DURT cells are optimally defined using tetramers or by detecting specific invariant TCRs. Staining of fixed cells with MR1–5OP-RU and CD1d-αGalCer tetramers, or anti-Vα24Jα18 TCR antibody was suboptimal, yielding very high inter-individual variability (MR1 tetramer) or poor staining resolution (CD1d- tetramer and anti-Vα24Jα18,) and these reagents were not included. Rather, anti-CD161 and anti-TRAV1.2 (Vα7.2) antibodies were used to phenotypically identify MAIT cells, while CD56 expression on T cells was used to identify NKT-like cells. Conventional CD4+ and CD8+ T cells were identified after exclusion of DURT cell subsets.
We included several markers to characterize lymphocyte differentiation. Expression levels of CCR7 and CD45RA were primarily used to distinguish between memory and naïve T cells and between memory and effector T cell compartments. Four main subsets were identified, namely naïve T cells, central memory T cells (CM), effector memory (EM) and terminally differentiated effector T cells (EMRA). While naïve T cells express both CCR7 and CD45RA, CM lose CD45RA during transition from naïve to memory stage. Following antigen exposure, CM lose CCR7 expression and differentiate into EM and, typically after chronic activation, finally into EMRA, which lack CCR7 and re-express CD45RA (16). CD27, CD57 and CD127 were used to further refine naïve and memory T cell subsets. CD27 is a co-stimulatory receptor important for activation of T cells during the early stages of differentiation. The oligosaccharide CD57 is an end-stage marker associated with T cell senescence and prone to activation-induced cell death. CD127 (IL-7 receptor α) regulates T cell homeostasis though proliferation and survival of memory T cells. As mentioned above, most of these differentiation markers can also be used to characterize lymphocyte subsets other than conventional T cells.
In this panel, we also included HLA-DR and CD38, which serve to differentiate myeloid cell subsets and identify activated T cells, as well as Ki-67, a proliferation marker expressed by all cell types during cell cycle. These activation markers are expressed for several days after in vivo upregulation, and are therefore useful to monitor ex vivo, non-specific activation of immune cells during infections and following treatment or vaccination (17–19).
To summarize, this panel enables identification and broad characterization of most relevant circulating leukocyte populations, including lymphoid and myeloid cell subsets and their phenotypes in human peripheral blood (Table 2). It may be used to track changes in immune cell subset abundance and expression of surface and intracellular markers that are modulated during different stages of infection and disease, as well as upon treatment, particularly by immunotherapy and vaccination. Importantly, we verified that all antibody clones included in the panel stained live, unfixed cells as well as fixed cells with similar performance. We recommend performing the same validation of individual antibodies and fluorochrome conjugates not reported here.
Table 2.
Specificity | Fluorochrome | Clone | Purpose | |
---|---|---|---|---|
CD45 | BV785 | HI30 | Leukocytes | Lineage |
CD66 | BV750 | B1.1 | Granulocytes | |
CD33 | PE-Cy5 | WM53 | Myeloid cells | |
CD14 | BB660 | MφP9 | Monocytes | |
CD11c | BUV661 | B-ly6 | Myeloid dendritic cells | |
CD19 | R718 | HIB19 | B cells | |
CD56 | BV711 | HCD56 | NK cells, NKT-like cells | |
CD127 | PE-Cy5.5 | eBioRD5 | ILCs, T cell differentiation | |
CD3 | BUV496 | UCHT-1 | T cells | |
CD4 | BV480 | SK3 | Helper T cells | |
CD8 | BV570 | RPA-T8 | Cytotoxic T cells | |
γδ TCR | BUV395 | B1 | γδ T cells | |
TRAV1.2 | PE | 3C10 | MAIT cells | |
CD161 | BV650 | DX12 | MAIT cells, T/NK cell differentiation | |
CD38 | BB700 | HIT2 | Monocyte, mDC, T cell, and B cell activation/differentiation, plasmablasts | Phenotype / cell subsets |
HLA-DR | BUV563 | G46-6 | Myeloid subsets, T cell activation | |
CD32 | BB630 | FLI8.26 | Fc receptor | |
CD16 | BV605 | 3G8 | Monocyte, NK, and mDC subsets | |
IgD | BUV737 | IA6-2 | B cell differentiation | |
CD27 | BUV805 | M-T271 | T, B, and NK cell differentiation | |
CD57 | BB515 | NK-1 | NK and T cell differentiation | |
CD45RA | APC-eFluor 780 | HI100 | T cell differentiation | |
CCR7 | PE-CF594 | 150503 | T cell differentiation | |
Vδ2 | BB790 | B6 | γδ T cell subset | |
Perforin | BV421 | γG9 | CD8, NK and NKT cell cytotoxicity | Function |
Granzyme B | AF647 | DH2 | CD8, NK and NKT-like cell cytotoxicity | |
Ki67 | PE-Cy7 | B56 | Proliferation |
2. Similarity to published OMIPs
Although OMIP-063, -069 and -078 focused on immune-profiling of major immune cell subsets by flow cytometry, these panels were optimized using PBMCs. To our knowledge, few extensive panels focusing on a broad range of leukocytes were developed on whole blood (OMIP-077, -062) and none used fixative prior to staining of extra-cellular markers. In fact, this 27-color panel is the first to enable comprehensive characterization of cellular composition of fixed and cryopreserved whole blood. This is particularly valuable to measure expression of surface and intracellular markers on most cell populations, especially when sample availability is limited, for example in paediatric studies or large clinical studies. Myeloid populations are defined using five of the 27 markers, while we identified lymphoid cells with nine markers. In addition, we included additional markers to allow characterization of ex vivo cell differentiation, activation, function and proliferation. HLA-DR, CD11c, CD16, CD32, CD38 and CD45RA can be expressed by both myeloid and lymphoid compartments.
3. Human samples
All participants provided written, informed consent and the protocol was approved by the Human Research Ethics Committee of University of Cape Town, South Africa. The study was conducted according to the principles of the Declaration of Helsinki. Venous WB was collected in sodium heparin tubes from healthy, adult donors.
Supplementary Material
Table 1.
Purpose | Broad immunophenotyping of leukocytes including myeloid (neutrophils, monocytes, mDCs) and lymphoid cell lineages (conventional T cells, DURT cells, γδ T cells, B cells, NK cells, ILCs) |
Species | Human |
Cell type | Fresh or fixed, cryopreserved whole blood |
Cross-references | OMIP-062, -063, -069, -077, -078 |
Acknowledgements
We thank One Dintwe, Erica Andersen-Nissen and the Cape Town HIV Immunology Laboratory for providing advice and access to their BD FACSymphony A5 instrument. We also would like to thank Thomas Liechti, Mario Roederer and Steve Perfetto from the Vaccine Research Center, NIH, for providing reagents and advice on panel design and gating strategy. In addition, we thank Katharine Schwedhelm and Stephen DeRosa, from the Fred Hutchinson Cancer Research Center for technical advice on high parameter flow cytometry and panel design. Finally, we thank Nicole Frahm from the Gates Medical Research Institute, and the leadership team of the TB Immune Correlate Program.
Funders:
Bill & Melinda Gates Foundation (INV-004813), US National Institutes of Health (R01 AI143636).
Footnotes
Conflict of interest
The authors have no conflict of interest to declare.
Bibliography
- 1.Nemes E, Fiore-Gartland A, Boggiano C, Coccia M, D’Souza P, Gilbert P, et al. The quest for vaccine-induced immune correlates of protection against tuberculosis. Vaccine Insights. 2022;1(3):165–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Nemes E, Kagina BM, Smit E, Africa H, Steyn M, Hanekom WA, et al. Differential leukocyte counting and immunophenotyping in cryopreserved ex vivo whole blood. Cytometry A. 2015;87(2):157–65. [DOI] [PubMed] [Google Scholar]
- 3.Imbratta C, Gela A, Bilek N, Mabwe S, Cloete Y, Mortensen R, et al. Qualification of the differential leukocyte count and immunophenotyping in cryopreserved ex vivo whole blood assay. Cytometry A. 2023. [DOI] [PubMed] [Google Scholar]
- 4.Burn GL, Foti A, Marsman G, Patel DF, Zychlinsky A. The Neutrophil. Immunity. 2021;54(7):1377–91. [DOI] [PubMed] [Google Scholar]
- 5.Cabeza-Cabrerizo M, Cardoso A, Minutti CM, Pereira da Costa M, Reis e Sousa C. Dendritic Cells Revisited. Annu Rev Immunol. 2021;39:131–66. [DOI] [PubMed] [Google Scholar]
- 6.Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl Med. 2020;12(553). [DOI] [PubMed] [Google Scholar]
- 7.Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol. 2008;8(1):34–47. [DOI] [PubMed] [Google Scholar]
- 8.Nutt SL, Hodgkin PD, Tarlinton DM, Corcoran LM. The generation of antibody-secreting plasma cells. Nat Rev Immunol. 2015;15(3):160–71. [DOI] [PubMed] [Google Scholar]
- 9.Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.White MJ, Nielsen CM, McGregor RH, Riley EH, Goodier MR. Differential activation of CD57-defined natural killer cell subsets during recall responses to vaccine antigens. Immunology. 2014;142(1):140–50. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood. 2010;116(19):3865–74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Lopez-Verges S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A. 2011;108(36):14725–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Venkatasubramanian S, Cheekatla S, Paidipally P, Tripathi D, Welch E, Tvinnereim AR, et al. IL-21-dependent expansion of memory-like NK cells enhances protective immune responses against Mycobacterium tuberculosis. Mucosal Immunol. 2017;10(4):1031–42. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Van Rhijn I, Moody DB. Donor Unrestricted T Cells: A Shared Human T Cell Response. J Immunol. 2015;195(5):1927–32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Papadopoulou M, Dimova T, Shey M, Briel L, Veldtsman H, Khomba N, et al. Fetal public Vgamma9Vdelta2 T cells expand and gain potent cytotoxic functions early after birth. Proc Natl Acad Sci U S A. 2020;117(31):18638–48. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24–35. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Musvosvi M, Duffy D, Filander E, Africa H, Mabwe S, Jaxa L, et al. T-cell biomarkers for diagnosis of tuberculosis: candidate evaluation by a simple whole blood assay for clinical translation. Eur Respir J. 2018;51(3). [DOI] [PubMed] [Google Scholar]
- 18.Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, et al. Biomarkers on patient T cells diagnose active tuberculosis and monitor treatment response. J Clin Invest. 2015;125(9):3723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Mpande CAM, Musvosvi M, Rozot V, Mosito B, Reid TD, Schreuder C, et al. Antigen-Specific T-Cell Activation Distinguishes between Recent and Remote Tuberculosis Infection. Am J Respir Crit Care Med. 2021;203(12):1556–65. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.